Zimmer Biomet To Acquire Embody
January 6, 2023 at 10:51 p.m.
By Staff Report-
The acquisition is expected to be accretive to overall revenue growth and slightly dilutive to adjusted earnings per share in 2023, according to a news release from Zimmer Biomet.
The acquisition includes Embody's complete portfolio of collagen-based biointegrative solutions to support healing in the most challenging orthopedic soft tissue injuries – including the TAPESTRY® biointegrative implant for tendon healing and TAPESTRY® RC, one of the first arthroscopic implant systems for rotator cuff repair.
"Embody's differentiated products and innovative pipeline in the area of sports medicine support our continued focus on and investment in high-growth markets and underscores our commitment to bringing meaningful new advances to patients and surgeons," said Bryan Hanson, chairman, president and CEO of Zimmer Biomet. "The planned acquisition of Embody is an important step in the ongoing transformation of ZB and the execution of our strategic priority to increase long-term growth and drive value creation."
"We are excited for the potential to create value for patients and customers in new ways and believe the combination of Embody's innovative products and Zimmer Biomet's established portfolio will bring new solutions to the market that could redefine the standard of care," said Jeff Conroy, chief executive officer of Embody.
The transaction is subject to customary closing conditions and is expected to be completed in February.
Guggenheim Securities is acting as financial advisor to Embody.
Latest News
E-Editions
The acquisition is expected to be accretive to overall revenue growth and slightly dilutive to adjusted earnings per share in 2023, according to a news release from Zimmer Biomet.
The acquisition includes Embody's complete portfolio of collagen-based biointegrative solutions to support healing in the most challenging orthopedic soft tissue injuries – including the TAPESTRY® biointegrative implant for tendon healing and TAPESTRY® RC, one of the first arthroscopic implant systems for rotator cuff repair.
"Embody's differentiated products and innovative pipeline in the area of sports medicine support our continued focus on and investment in high-growth markets and underscores our commitment to bringing meaningful new advances to patients and surgeons," said Bryan Hanson, chairman, president and CEO of Zimmer Biomet. "The planned acquisition of Embody is an important step in the ongoing transformation of ZB and the execution of our strategic priority to increase long-term growth and drive value creation."
"We are excited for the potential to create value for patients and customers in new ways and believe the combination of Embody's innovative products and Zimmer Biomet's established portfolio will bring new solutions to the market that could redefine the standard of care," said Jeff Conroy, chief executive officer of Embody.
The transaction is subject to customary closing conditions and is expected to be completed in February.
Guggenheim Securities is acting as financial advisor to Embody.
Have a news tip? Email [email protected] or Call/Text 360-922-3092